70024-40-7 Terazosin HCl dihydrate AKSci J10542
 
 
Loading Please Wait...
  J10542    
Terazosin HCl dihydrate
, >98% (HPLC)
 
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2- furoyl)piperazine monohydrochloride dihydrate




IDENTITY
CAS Number:70024-40-7
MDL Number:MFCD00941408
MF:C19H30ClN5O6
MW:459.92
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:271-274°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:Soluble in water
Application(s):alpha1-Antagonist
Form:HCl salt

REVIEW

 In general, alpha1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. alpha1-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three alpha1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: alpha1A (chromosome 8), alpha1B (chromosome 5), and alpha1D (chromosome 20). Terazosin is the first alpha1-receptor antagonist to demonstrate selectivity for the alpha1A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The alpha1A-receptor maintains basal vascular tone while the alpha1B-receptor mediates the vasocontrictory effects of exogenous alpha1-agonists. Activation of alpha1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting alpha1A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.

REFERENCES
[1]Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of September 22, 2024


Download SDS Request COA

All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Alpha Blocker


PubChem